Selecta Biosciences, Inc. Share Based Compensation of Revenue

Share Based Compensation of Revenue of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Share Based Compensation of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Share Based Compensation of Revenue for the quarter ending December 30, 2020 was 10.34% (a -62.93% decrease compared to previous quarter)
  • Year-over-year quarterly Share Based Compensation of Revenue increased by Infinity%
  • Annual Share Based Compensation of Revenue for 2020 was 32.67% (a -57.74% decrease from previous year)
  • Annual Share Based Compensation of Revenue for 2019 was 77.3% (a -87.78% decrease from previous year)
  • Annual Share Based Compensation of Revenue for 2018 was 632.78% (a -67.9% decrease from previous year)
  • Twelve month Share Based Compensation of Revenue ending December 30, 2020 was 23.31% (a -52.98% decrease compared to previous quarter)
  • Twelve month trailing Share Based Compensation of Revenue increased by Infinity% year-over-year
Trailing Share Based Compensation of Revenue for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
23.31% 49.57% 0.0% 0.0%
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Share Based Compensation of Revenue of Selecta Biosciences, Inc.

Most recent Share Based Compensation of Revenueof SELB including historical data for past 10 years.

Interactive Chart of Share Based Compensation of Revenue of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Share Based Compensation of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 10.34% 27.89% 0.0% 0.0% 32.67%
2019 21.45% 0.0% 9623.08% 11800.0% 77.3%
2018 0.0% 0.0% 0.0% 0.0% 632.78%
2017 7111.76% 4866.67% 3326.92% 505.84% 1971.5%
2016 26.28% 60.31% 18.2% 13.51% 25.37%
2015 15.68% 49.92% 18.72%
2014 40.26%

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.